A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Dose of GZ402668 in Men and Women With Progressive Multiple Sclerosis
Phase of Trial: Phase I
Latest Information Update: 06 Apr 2018
At a glance
- Drugs GZ 402668 (Primary) ; Aciclovir
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Sanofi
- 29 Mar 2018 Planned End Date changed from 13 Mar 2018 to 30 Apr 2018.
- 29 Mar 2018 Planned primary completion date changed from 13 Mar 2018 to 30 Apr 2018.
- 29 Mar 2018 Status changed from active, no longer recruiting to recruiting.